Diagnostic accuracy of the Aspergillus ‐specific bronchoalveolar lavage lateral‐flow assay in haematological malignancy patients
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: We evaluated the performance of the Aspergillus ‐specific lateral‐flow device ( LFD ) test for diagnosing invasive pulmonary aspergillosis ( IPA ) in patients with underlying haematological malignancies. Participating centres were the two Austrian University Hospitals of Graz and Innsbruck. LFD performance was evaluated with 95 bronchoalveolar lavage fluid ( BALF ) samples from 72 patients collected prospectively in Graz, and with 24 BALF bio bank samples from 23 patients (21 samples with probable IPA ) in Innsbruck. Invasive fungal infections were classified according to the revised European Organization of Research and Treatment of Cancer/Mycoses Study Group criteria. Overall, 27 patients (30 samples) had probable IPA , 32 (43 samples) possible and 36 (46 samples) did not fulfil IPA criteria. The vast majority of patients – in particular those with probable IPA – received mould‐active treatment before bronchoscopy. Sensitivity, specificity, positive predictive value and negative‐predictive‐value for probable IPA diagnosis using the BALF ‐ LFD test were 71%, 76%, 35% and 94% for the Graz cohort. Sensitivity of the BALF ‐ LFD test for probable IPA was 57% in Innsbruck bio bank samples. Our results indicate that the BALF ‐ LFD ‐test provides fast results with moderate sensitivities in patients with underlying haematological malignancies. Similar to other diagnostic tests and biomarkers sensitivity of the test may be influenced by ongoing systemic mould‐active treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Hoenigl, M., Prattes, J., Spiess, B., Wagner, J., Prueller, F., Raggam, R. B., Posch, V., Duettmann, W., Hoenigl, K., Wölfler, A., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00467-14 · Cited by 233
Self-citationThornton, C. R. (2008) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00068-08 · Cited by 226 · cited 1×
“Decreased sensitivities under mouldactive treatment have also been reported for BALF GM,(23) PCR and culture.(18) Timing of bronchoscopy therefore seems a very important factor that influences performance of BALF biomarkers. Negative BALF biomarkers may only help to rule out IPA if obtained during early stages of the…”
Self-citationNucci, M., Nouér, S. A., Grazziutti, M., Kumar, N. S., Barlogie, B., & Anaissie, E. (2010) · Clinical Infectious Diseases · doi:10.1086/657065 · Cited by 112
Reinwald, M., Spiess, B., Heinz, W. J., Vehreschild, J. J., Lass‐Flörl, C., Kiehl, M., Schultheis, B., Krause, S. W., Wolf, H., Bertz, H., et al. (2012) · European Journal of Haematology · doi:10.1111/j.1600-0609.2012.01806.x · Cited by 67
Self-citationGalactomannan in Bronchoalveolar Lavage for Diagnosing Invasive Fungal Disease
Affolter, K., Tamm, M., Jahn, K., Halter, J., Passweg, J., Hirsch, H. H., & Stolz, D. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0431oc · Cited by 51
Cited by
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationHeldt, S., Prattes, J., Eigl, S., Spiess, B., Flick, H., Rabensteiner, J., Johnson, G., Prüller, F., Wölfler, A., Niedrist, T., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.05.001 · Cited by 110
“Introduction Invasive mold infections (IMI) including invasive aspergillosis (IA) are associated with high morbidity and mortality among patients with underlying hematological malignancies [1, 2].”
BackgroundSelf-citationChronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
Hayes, G., & Novak-Frazer, L. (2016) · Journal of Fungi · doi:10.3390/jof2020018 · Cited by 77
An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections
Jenks, J. D., White, P. L., Kidd, S. E., Goshia, T., Fraley, S. I., Hoenigl, M., & Thompson, G. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2267977 · Cited by 61
“…Aspergillus -specific Lateral Flow Device (LFD) (OLM Diagnostics, Newcastle upon Tyne, United Kingdom) and the Aspergillus Galactomannan Lateral Flow Assay (LFA) (IMMY, Norman, Oklahoma, United States) are also lower for individuals on mold-active treatment and those without neutropenia [30,35,36].”
BackgroundSelf-citationJenks, J. D., Mehta, S. R., Taplitz, R., Law, N., Reed, S. L., & Hoenigl, M. (2019) · Journal of Infection · doi:10.1016/j.jinf.2018.10.014 · Cited by 54
Self-citationZhang, L., Guo, Z., Xie, S., Zhou, J., Chen, G., Feng, J., & Huang, Y. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.08.005 · Cited by 36
Diagnostics and Susceptibility Testing in Aspergillus
Bernal-Martínez, L., Alastruey-Izquierdo, A., & Cuenca-Estrella, M. (2016) · Future Microbiology · doi:10.2217/fmb.15.140 · Cited by 25
Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8
“The antigen is an Aspergillus-specific mannoprotein that is detected by JF5 monoclonal antibodies [103].”
Background
Metadata
- Authors
- Prattes, J., Lackner, M., Eigl, S., Reischies, F., Raggam, R. B., Koidl, C., Flick, H., Wurm, R., Palfner, M., Wölfler, A., Neumeister, P., Thornton, C. R., Krause, R., Lass‐Flörl, C., & Hoenigl, M.
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 2015-06-23
- Volume
- 58
- Issue
- 8
- Pages
- 461-469
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W1936387837
- Cited by
- 60
- References
- 6
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.